Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined convalescent plasma plus oral RdRp inhibitor vs monoclonal neutralizing antibody in mild to moderate outpatient COVID-19
TCTR20220319002Phase 3Completed
- Sponsor
- Chulabhorn Royal Academy
- Start
- Jan 2022
- Countries
- 1
01
Overview
A Phase 3 trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19), sponsored by Chulabhorn Royal Academy. Started Jan 2022; status: completed.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220319002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220319002.